Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.61 |
| ▸ | CES1 | P23141 | 4/20 | 0.61 |
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | YAP1 | P46937 | 1/20 | 0.40 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30956722 | 1.00 | CES2 (0.61) | CES2CES1BCHEHPGDALDH1A1 | |
| SCHEMBL27203892 | 0.85 | CES2 (0.57) | CES2CES1BCHEHPGDALDH1A1 | |
| SCHEMBL1427156 | 0.83 | ALDH1A1 (0.59) | CES2CES1BCHEHPGDALDH1A1 | |
| SCHEMBL29779889 | 0.83 | ALDH1A1 (0.59) | CES2CES1BCHEHPGDALDH1A1 | |
| SCHEMBL14396511 | 0.82 | CES2 (0.63) | CES2CES1BCHEHPGDALDH1A1 | |
| SCHEMBL13722818 | 0.82 | CES2 (0.63) | CES2CES1BCHEHPGDALDH1A1 | |
| SCHEMBL15990788 | 0.82 | CES2 (0.63) | CES2CES1BCHEHPGDALDH1A1 | |
| SCHEMBL9612851 | 0.82 | CES2 (0.59) | CES2CES1BCHEALDH1A1DRD2 | |
| SCHEMBL633282 | 0.80 | CES2 (0.61) | CES2CES1BCHEHPGDALDH1A1 | |
| SCHEMBL31599609 | 0.80 | CES2 (0.61) | CES2CES1BCHEHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2025-04-22 | — | — | US | disclosed |
| CN-111148731-B | Fluorophenyl beta-hydroxyethylamine and its use in the treatment of hyperglycaemia | 阿托基公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-16 | — | — | US | disclosed |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-16 | — | — | US | disclosed |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-16 | — | — | US | disclosed |
| EP-3681857-B1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| EP-3681857-B1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2023-11-08 | — | — | EP | disclosed |
| EP-4249054-A2 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2023-09-27 | — | — | EP | disclosed |
| EP-4249054-A2 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2023-09-27 | — | — | EP | disclosed |
| US-11648216-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | ATROGI AB (SE) | 2023-05-16 | — | — | US | disclosed |
| EP-2007764-A1 | PROCESS FOR THE PREPARATION OF CGRP ANTAGONIST | Merck & Co., Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-2007395-A1 | CGRP ANTAGONIST SALT | Merck & Co., Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| EP-2007763-A2 | PROCESS FOR THE PREPARATION OF PYRIDINE HETEROCYCLE CGRP ANTAGONIST INTERMEDIATE | Merck & Co., Inc. (US) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007120589-A2 | PROCESS FOR THE PREPARATION OF CAPROLACTAM CGRP ANTAGONIST INTERMEDIATE | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120591-A1 | PROCESS FOR THE PREPARATION OF CGRP ANTAGONIST | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120591-A1 | PROCESS FOR THE PREPARATION OF CGRP ANTAGONIST | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120592-A1 | CGRP ANTAGONIST SALT | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120592-A1 | CGRP ANTAGONIST SALT | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120590-A2 | PROCESS FOR THE PREPARATION OF PYRIDINE HETEROCYCLE CGRP ANTAGONIST INTERMEDIATE | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120590-A2 | PROCESS FOR THE PREPARATION OF PYRIDINE HETEROCYCLE CGRP ANTAGONIST INTERMEDIATE | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280023-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | GPR119, SLC5A2, SLC5A1 | CES2 190/4885CES1 323/4885BCHE 92/4885 |
| US-20230364035-A1 | FLUOROPHENYL BETA-HYDROXYETHYLAMINES AND THEIR USE IN THE TREATMENT OF HYPERGLYCAEMIA | GPR119, SLC5A2, SLC5A1 | CES2 190/4885CES1 323/4885BCHE 92/4885 |
| US-11648216-B2 | Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia | GPR119, SLC5A2, SLC5A1 | CES2 190/4885CES1 323/4885BCHE 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.